Drug Trial Radar · NCT05347498
A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Apr 30, 2022
Primary completion
Jul 31, 2022
Study completion Jul 31, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
Conditions
- Primary Gout With Hyperuricemia in Adults
Interventions
HR091506 tablets + placebo of febuxostat tabletsDrug
HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
febuxostat tablets + placebo of HR091506 tabletsDrug
febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects with serum uric acid level < 360μmol/L on Day 15.Time frame: on Day 15.
- Proportion of subjects with serum uric acid level < 360μmol/L at test of cure (TOC)Time frame: Test of cure, defined as the day after end of treatment, equivalent to Study Day 15 or 29
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.